Department / Division
Pediatrics / Pediatrics-Hematology/Oncology
Durham, NC 27710
Advanced treatments for neuroblastoma, pediatric solid tumors, leukemia
Neuroblastoma is the most common extra-cranial solid tumor of childhood. Despite advances in the treatment of childhood cancer, outcomes for children with advanced-stage neuroblastoma remain poor. My basic science research interests are focused on understanding the physiology of the neuroblastoma cell and what it does to circumvent the effects of chemotherapy. Additionally, I am interested in translational research in neuroblastoma. We have open trials for therapeutic MIBG and anti-GD2 antibody treatment for neuroblastoma. Clinically, I am involved in the treatment of childhood malignancies including neuroblasotma, soft tissue sarcomas, and leukemia. Additionally, I have an interest in the management of vascular malformations, such as hemangioma.
This faculty member has no reported relationships with industry.
Armstrong, MB; Schumacher, KR; Mody, R; Yanik, GA; Opipari, AW; Castle, VP. Bortezomib as a therapeutic candidate for neuroblastoma. Journal of Experimental Therapeutics and Oncology. 2008;7:135-145. (2008) Abstract
Armstrong, MB; Bian, X; Liu, Y; Subramanian, C; Ratanaproeksa, AB; Shao, F; Yu, VC; Kwok, RP; Opipari, AW; Castle, VP. Signaling from p53 to NF-kappaB determines the chemotherapy responsiveness of neuroblastoma. Neoplasia. 2006;8:967-977. (2006) Abstract
Armstrong, MB; Robertson, PL; Castle, VP. Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis. Pediatric Neurology. 2005;33:365-367. (2005) Abstract